73 related articles for article (PubMed ID: 15857750)
1. 5beta-Cholane activators of the farnesol X receptor.
Fukuchi J; Song C; Dai Q; Hiipakka RA; Liao S
J Steroid Biochem Mol Biol; 2005 Mar; 94(4):311-8. PubMed ID: 15857750
[TBL] [Abstract][Full Text] [Related]
2. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.
Pineda Torra I; Claudel T; Duval C; Kosykh V; Fruchart JC; Staels B
Mol Endocrinol; 2003 Feb; 17(2):259-72. PubMed ID: 12554753
[TBL] [Abstract][Full Text] [Related]
3. Bile acid signaling through FXR induces intracellular adhesion molecule-1 expression in mouse liver and human hepatocytes.
Qin P; Borges-Marcucci LA; Evans MJ; Harnish DC
Am J Physiol Gastrointest Liver Physiol; 2005 Aug; 289(2):G267-73. PubMed ID: 15817812
[TBL] [Abstract][Full Text] [Related]
4. The cholesterol-raising factor from coffee beans, cafestol, as an agonist ligand for the farnesoid and pregnane X receptors.
Ricketts ML; Boekschoten MV; Kreeft AJ; Hooiveld GJ; Moen CJ; Müller M; Frants RR; Kasanmoentalib S; Post SM; Princen HM; Porter JG; Katan MB; Hofker MH; Moore DD
Mol Endocrinol; 2007 Jul; 21(7):1603-16. PubMed ID: 17456796
[TBL] [Abstract][Full Text] [Related]
5. The novel compounds that activate farnesoid X receptor: the diversity of their effects on gene expression.
Suzuki T; Tamehiro N; Sato Y; Kobayashi T; Ishii-Watabe A; Shinozaki Y; Nishimaki-Mogami T; Hashimoto T; Asakawa Y; Inoue K; Ohno Y; Yamaguchi T; Kawanishi T
J Pharmacol Sci; 2008 Jul; 107(3):285-94. PubMed ID: 18603830
[TBL] [Abstract][Full Text] [Related]
6. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c.
Watanabe M; Houten SM; Wang L; Moschetta A; Mangelsdorf DJ; Heyman RA; Moore DD; Auwerx J
J Clin Invest; 2004 May; 113(10):1408-18. PubMed ID: 15146238
[TBL] [Abstract][Full Text] [Related]
7. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids.
Kast HR; Nguyen CM; Sinal CJ; Jones SA; Laffitte BA; Reue K; Gonzalez FJ; Willson TM; Edwards PA
Mol Endocrinol; 2001 Oct; 15(10):1720-8. PubMed ID: 11579204
[TBL] [Abstract][Full Text] [Related]
8. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia.
Evans MJ; Mahaney PE; Borges-Marcucci L; Lai K; Wang S; Krueger JA; Gardell SJ; Huard C; Martinez R; Vlasuk GP; Harnish DC
Am J Physiol Gastrointest Liver Physiol; 2009 Mar; 296(3):G543-52. PubMed ID: 19136377
[TBL] [Abstract][Full Text] [Related]
9. 5Alpha-bile alcohols function as farnesoid X receptor antagonists.
Nishimaki-Mogami T; Kawahara Y; Tamehiro N; Yoshida T; Inoue K; Ohno Y; Nagao T; Une M
Biochem Biophys Res Commun; 2006 Jan; 339(1):386-91. PubMed ID: 16300737
[TBL] [Abstract][Full Text] [Related]
10. Hypolipidemic effects and mechanisms of Panax notoginseng on lipid profile in hyperlipidemic rats.
Ji W; Gong BQ
J Ethnopharmacol; 2007 Sep; 113(2):318-24. PubMed ID: 17681443
[TBL] [Abstract][Full Text] [Related]
11. Polyunsaturated fatty acids are FXR ligands and differentially regulate expression of FXR targets.
Zhao A; Yu J; Lew JL; Huang L; Wright SD; Cui J
DNA Cell Biol; 2004 Aug; 23(8):519-26. PubMed ID: 15307955
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of ATP8B1 expression leads to specific downregulation of the bile acid sensor FXR in HepG2 cells: effect of the FXR agonist GW4064.
Martínez-Fernández P; Hierro L; Jara P; Alvarez L
Am J Physiol Gastrointest Liver Physiol; 2009 May; 296(5):G1119-29. PubMed ID: 19228886
[TBL] [Abstract][Full Text] [Related]
13. Regulation of carbohydrate metabolism by the farnesoid X receptor.
Stayrook KR; Bramlett KS; Savkur RS; Ficorilli J; Cook T; Christe ME; Michael LF; Burris TP
Endocrinology; 2005 Mar; 146(3):984-91. PubMed ID: 15564327
[TBL] [Abstract][Full Text] [Related]
14. Hypolipidemic activity and mechanism of purified herbal extract of Salvia miltiorrhiza in hyperlipidemic rats.
Ji W; Gong BQ
J Ethnopharmacol; 2008 Sep; 119(2):291-8. PubMed ID: 18691646
[TBL] [Abstract][Full Text] [Related]
15. Expression and activation of the farnesoid X receptor in the vasculature.
Bishop-Bailey D; Walsh DT; Warner TD
Proc Natl Acad Sci U S A; 2004 Mar; 101(10):3668-73. PubMed ID: 14990788
[TBL] [Abstract][Full Text] [Related]
16. Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters.
Bilz S; Samuel V; Morino K; Savage D; Choi CS; Shulman GI
Am J Physiol Endocrinol Metab; 2006 Apr; 290(4):E716-22. PubMed ID: 16291572
[TBL] [Abstract][Full Text] [Related]
17. Liver X receptor and farnesoid X receptor as therapeutic targets.
Rader DJ
Am J Cardiol; 2007 Dec; 100(11 A):n15-9. PubMed ID: 18047847
[TBL] [Abstract][Full Text] [Related]
18. The farnesoid X receptor induces very low density lipoprotein receptor gene expression.
Sirvent A; Claudel T; Martin G; Brozek J; Kosykh V; Darteil R; Hum DW; Fruchart JC; Staels B
FEBS Lett; 2004 May; 566(1-3):173-7. PubMed ID: 15147890
[TBL] [Abstract][Full Text] [Related]
19. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy.
Jiang T; Wang XX; Scherzer P; Wilson P; Tallman J; Takahashi H; Li J; Iwahashi M; Sutherland E; Arend L; Levi M
Diabetes; 2007 Oct; 56(10):2485-93. PubMed ID: 17660268
[TBL] [Abstract][Full Text] [Related]
20. Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries.
Nicolaou KC; Evans RM; Roecker AJ; Hughes R; Downes M; Pfefferkorn JA
Org Biomol Chem; 2003 Mar; 1(6):908-20. PubMed ID: 12929628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
